乌司奴单抗治疗克罗恩病五年疗效与安全性:IM-UNITI 试验
IM-UNITI 研究及其长期延伸(LTE)评估皮下乌司奴单抗维持治疗克罗恩病的长期疗效、安全性和免疫原性,报告至 5 年的最终结果。维持期基线随机至乌司奴单抗的患者中,每 8 周组和每 12 周组分别有 34.4% 和 28.7% 在第 252 周处于临床缓解;进入 LTE 的患者中相应缓解率为 54.9% 和 45.2%。总体不良事件率在安慰剂组与乌司奴单抗合并组间 generally 相似,未观察到新的安全性信号。
要点
- 每 8 周组第 252 周临床缓解率 34.4%,每 12 周组 28.7%(ITT 人群)。
- 进入 LTE 的患者第 252 周缓解率分别为 54.9% 和 45.2%。
- 不良事件率在安慰剂与乌司奴单抗合并组间总体相似,无新安全性信号。
核心结论
- 接受皮下乌司奴单抗治疗的患者维持临床缓解至 5 年,未观察到新的安全性信号。
研究设计与样本
- IM-UNITI 研究及其长期延伸(LTE),纳入完成维持研究第 44 周安全性和疗效评估的患者继续原治疗。
- LTE 期间未调整剂量,疗效评估每 12 周一次直至揭盲,此后至第 252 周在给药访视时评估。
- 血清乌司奴单抗浓度和抗药抗体分别评估至第 252 周和第 272 周。
主要发现
- 维持期基线随机至乌司奴单抗的 ITT 人群中,每 8 周组 34.4%、每 12 周组 28.7% 在第 252 周处于临床缓解。
- 进入 LTE 的患者中,每 8 周组和每 12 周组第 252 周临床缓解率分别为 54.9% 和 45.2%。
- 维持期第 0 周至最终访视,安慰剂组与乌司奴单抗合并组的所有不良事件率(每 100 患者年)分别为 440.3 和 327.6。
- 严重不良事件率分别为 19.3 和 17.5,感染率分别为 99.8 和 93.8,严重感染率分别为 3.9 和 3.4(每 100 患者年)。
- LTE 期间血清乌司奴单抗浓度维持稳定;接受诱导和维持治疗并继续进入 LTE 的患者中 5.8% 出现抗药抗体。
临床怎么用
- 皮下乌司奴单抗可用于克罗恩病的长期维持治疗,5 年随访中疗效持续且安全性可控。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The IM-UNITI study and long-term extension (LTE) evaluated the long-term efficacy, safety, and immunogenicity of subcutaneous ustekinumab maintenance therapy in patients with Crohn's disease. Here, we report the final results of IM-UNITI LTE through 5 years. METHODS: Patients completing safety and efficacy evaluations at week 44 of the maintenance study were eligible to participate in the LTE and continue the treatment they were receiving. Unblinding occurred after completion of maintenance study analyses (August 2015), and patients receiving placebo were discontinued from the study after unblinding. No dose adjustment occurred in the LTE. Efficacy assessments were conducted every 12 weeks until unblinding and at dosing visits thereafter through week 252. Serum ustekinumab concentrations and antidrug antibodies were evaluated through weeks 252 and 272, respectively. RESULTS: Using an intent-to-treat analysis of all patients randomized to ustekinumab at maintenance baseline, 34.4% of patients in the every-8-weeks group and 28.7% in the every-12-weeks group were in clinical remission at week 252. Corresponding remission rates among patients who entered the LTE were 54.9% and 45.2%. Overall, adverse event rates (per 100 patient-years) from maintenance week 0 through the final visit generally were similar in the placebo and combined ustekinumab groups for all adverse events (440.3 vs 327.6), serious adverse events (19.3 vs 17.5), infections (99.8 vs 93.8), and serious infections (3.9 vs 3.4). Serum ustekinumab concentrations were maintained throughout the LTE. Antidrug antibodies occurred in 5.8% of patients who received ustekinumab during induction and maintenance and continued in the LTE. CONCLUSIONS: Patients receiving subcutaneous ustekinumab maintained clinical remission through 5 years. No new safety signals were observed. ClinicalTrials.gov number NCT01369355.
引用
- Sandborn WJ, Rebuck R, Wang Y, et al. Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial. Clin Gastroenterol Hepatol. 2021. PMID: 33618023. doi:10.1016/j.cgh.2021.02.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。